321970-25-6

Usage

Molecular structure

1H-Imidazole-4,5-dicarboxylic acid, 1-(phenylmethyl)-, dimethyl ester consists of an imidazole ring with a phenylmethyl group attached to the nitrogen atom at position 1, and two carboxylic acid groups at positions 4 and 5. The carboxylic acid groups are esterified with dimethyl groups.

Molecular weight

285.29 g/mol

Functional groups

Imidazole ring, phenylmethyl group, carboxylic acid groups, and ester groups.

Potential applications

Pharmaceutical development (targeting specific biological processes), synthesis of new materials, and research as a reagent or catalyst.

Safety precautions

Handle and use with care, and follow appropriate safety guidelines to avoid potential hazards.

Upstream product

• 3304-70-9 dimethyl imidazole-4,5-dicarboxylate 
• 100-39-0 benzyl bromide 

Downstream Products

• 42190-83-0 1-benzyl-4,5-imidazoledicarboxylic acid 
• 684287-01-2 1-benzyl-6-(4-fluorobenzyl)-4,8-dihydroxy-1H-1,3,6-triaza-s-indacene-5,7-dione 
• 5424-28-2 1-benzyl-5,6-dihydro-1H-imidazo[4,5-d]pyridazine-4,7-dione 
• 86281-18-7 dicyclohexyldiamide of 1-benzyl-4,5-imidazoledicarboxylic acid 
• 42190-85-2 1-Benzyl-1H-imidazole-4,5-dicarbonyl dichloride 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS

The invention relates to a compound of Formula I, pharmaceutical compositions comprising a compound of Formula I, and methods of treating cystic fibrosis comprising the step of administering a therapeutically effective amount of a compound of Formula I to

Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring

This communication details both the syntheses and biological evaluation of a novel class of HIV-1 integrase inhibitors. When the quinoline moiety is replaced with the quinoxoline moiety, the antiviral activity is significantly compromised. Similarly, intr

PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS

Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

HIV INTEGRASE INHIBITORS

The present invention concerns the compounds having the formula (1), N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof wherein (a) or (b); A, together with the two carbons of the phenyl ring to which it is attached forms a monocyclic aryl or a monocyclic Het2 ; R1 is hydrogen, halo, nitro, cyano, sultam, sulltim, C3-7cycloalkyl, C(=O)-R5, S(=O)y-R6, OR 7, NR8R9, C(=NR8)-R5, optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl; R 2 is hydrogen, C3-7cycloalkyl, aryl, Het1, Het2, C(=O)-R5, S(=O)Y-R6 OR7, NR8R9, C=NR8)-R5, or optionally polysubstituted C1-6alkyl, optionally polysubstituted C2-6alkenyl or optionally polysubstituted C2-6alkynyl. It further relates to their use as HIV integrase inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. It also concerns combinations thereof with other anti-retroviral agents, and to their use in assays as reference compounds or as reagents.

1-ALKYL- AND 1-GLUCOSYL-4,5-IMIDAZOLEDICARBOXAMIDES

Among 4,5-imidazoledicarboxamides compounds were found which possess clearly defined neurotropic activity.In order to study the relation between the structure and the activity a series a new 4,5-imidazoledicarboxamides substituted in the amide groups and at the nitrogen of the imidazole ring were obtained.Their syntheses and characteristics are described.